139 related articles for article (PubMed ID: 22547411)
1. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--no.
Filippi M; Rocca MA
Mult Scler; 2012 May; 18(5):557-8. PubMed ID: 22547411
[No Abstract] [Full Text] [Related]
2. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--yes.
Geurts JJ
Mult Scler; 2012 May; 18(5):559-60. PubMed ID: 22547412
[No Abstract] [Full Text] [Related]
3. Gray matter atrophy in multiple sclerosis: a longitudinal study.
Fisher E; Lee JC; Nakamura K; Rudick RA
Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
[TBL] [Abstract][Full Text] [Related]
4. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--commentary.
Hutchinson M
Mult Scler; 2012 May; 18(5):561-2. PubMed ID: 22547413
[No Abstract] [Full Text] [Related]
5. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
[TBL] [Abstract][Full Text] [Related]
6. Rate of brain atrophy in benign vs early multiple sclerosis.
Gauthier SA; Berger AM; Liptak Z; Duan Y; Egorova S; Buckle GJ; Glanz BI; Khoury SJ; Bakshi R; Weiner HL; Guttmann CR
Arch Neurol; 2009 Feb; 66(2):234-7. PubMed ID: 19204160
[TBL] [Abstract][Full Text] [Related]
7. MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.
Jacobsen CO; Farbu E
Acta Neurol Scand Suppl; 2014; (198):32-6. PubMed ID: 24588504
[TBL] [Abstract][Full Text] [Related]
8. Brain atrophy and lesion load in a large population of patients with multiple sclerosis.
Tedeschi G; Lavorgna L; Russo P; Prinster A; Dinacci D; Savettieri G; Quattrone A; Livrea P; Messina C; Reggio A; Bresciamorra V; Orefice G; Paciello M; Brunetti A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Patti F; Salemi G; Cammarata E; Simone IL; Salvatore M; Bonavita V; Alfano B
Neurology; 2005 Jul; 65(2):280-5. PubMed ID: 16043800
[TBL] [Abstract][Full Text] [Related]
9. Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging.
Chard D; Miller D
J Neurol Sci; 2009 Jul; 282(1-2):5-11. PubMed ID: 19201002
[TBL] [Abstract][Full Text] [Related]
10. Functional faults: fMRI in MS.
Phillips MD
Neurology; 2008 Jan; 70(4):248-9. PubMed ID: 18209198
[No Abstract] [Full Text] [Related]
11. [Functional magnetic resonance imaging in multiple sclerosis].
Korsholm K; Mathiesen HK; Lund TE
Ugeskr Laeger; 2007 Jun; 169(26):2518-20. PubMed ID: 17725897
[TBL] [Abstract][Full Text] [Related]
12. Evidence of thalamic gray matter loss in pediatric multiple sclerosis.
Mesaros S; Rocca MA; Absinta M; Ghezzi A; Milani N; Moiola L; Veggiotti P; Comi G; Filippi M
Neurology; 2008 Mar; 70(13 Pt 2):1107-12. PubMed ID: 18272867
[TBL] [Abstract][Full Text] [Related]
13. Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis.
Foster M; Zivadinov R; Weinstock-Guttman B; Tamaño-Blanco M; Badgett D; Carl E; Ramanathan M
J Neuroimmunol; 2012 Feb; 243(1-2):61-8. PubMed ID: 22261546
[TBL] [Abstract][Full Text] [Related]
14. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis.
Sastre-Garriga J; Arévalo MJ; Renom M; Alonso J; González I; Galán I; Montalban X; Rovira A
J Neurol Sci; 2009 Jul; 282(1-2):120-4. PubMed ID: 19157420
[TBL] [Abstract][Full Text] [Related]
15. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
[TBL] [Abstract][Full Text] [Related]
16. Starting early: MRI evidence of gray matter atrophy in children with multiple sclerosis.
Banwell BL; Sled JG
Neurology; 2008 Mar; 70(13 Pt 2):1065-6. PubMed ID: 18362266
[No Abstract] [Full Text] [Related]
17. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis.
Santos AC; Narayanan S; de Stefano N; Tartaglia MC; Francis SJ; Arnaoutelis R; Caramanos Z; Antel JP; Pike GB; Arnold DL
J Neurol; 2002 Jun; 249(6):662-8. PubMed ID: 12111296
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
Sormani MP; Bonzano L; Roccatagliata L; De Stefano N
Mult Scler; 2011 May; 17(5):630-3. PubMed ID: 21177320
[TBL] [Abstract][Full Text] [Related]
19. Visualizing the cause of gray matter atrophy in multiple sclerosis.
Richert ND; Kraft E; Stüve O
Arch Neurol; 2009 Feb; 66(2):159-60. PubMed ID: 19204151
[No Abstract] [Full Text] [Related]
20. Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: a voxel-based morphometry study.
Duan Y; Liu Y; Liang P; Jia X; Yu C; Qin W; Sun H; Liao Z; Ye J; Li K
Eur J Radiol; 2012 Feb; 81(2):e110-4. PubMed ID: 21316170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
